X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases, including primary immunodeficiencies and certain cancer types. The company was founded in 2014 and is led by a team with extensive biopharmaceutical product development and commercialization expertise. X4 Pharmaceuticals is committed to advancing the development of innovative medicines on behalf of patients with limited treatment options.